Ovarian cancer is a worldwide health issue that grows at a rate of almost 250,000 new cases every year. Its early detection is key for a good prognosis and even curative surgery. However, current medical examination methods and tests have been inefficient in detecting ovarian cancer at the early stage, leading to preventable death. So far, new screening tests based on molecular biomarker analysis techniques have not resulted in any substantial improvement in early-stage diagnosis and increased survival. Thus, whilst there remains clear potential to improve outcomes through early detection, novel approaches are needed. Here, we postulated that MALDI-ToF-mass-spectrometry-based tests can be a solution for effective screening of ovarian cancer. In this retrospective cohort study, we generated and analyzed the mass spectra of 181 serum samples of women with and without ovarian cancer. Using bioinformatics pipelines for analysis, including predictive modeling and machine learning, we found distinct mass spectral patterns composed of 9–20 key combinations of peak intensity or peak enrichment features for each stage of ovarian cancer. Based on a scoring algorithm and obtained patterns, the optimal sensitivity for detecting each stage of cancer was 95–97% with a specificity of 97%. Scoring all algorithms simultaneously could detect all stages of ovarian cancer at 99% sensitivity and 92% specificity. The results further demonstrate that the matrix and mass range analyzed played a key role in improving the mass spectral data quality and diagnostic power. Altogether, with the results reported here and increasing evidence of the MS assay’s diagnostic accuracy and instrument robustness, it has become imminent to consider MS in the clinical application for ovarian cancer screening.
Screening programs for genetic and metabolic diseases such as haemoglobinopathies, thalassemias and diabetes are a worldwide problem that faces economic and technological limitations. This is mainly because genetic and metabolic tests are too expensive and time consuming to be implemented. MALDI-ToF mass spectrometry is a rapid and affordable high throughput technique with diagnostic potential for these diseases but still constrained by the timing and complexity of data analysis. To overcome this technological limitation, we developed a fully automated software solution in our MALDI-ToF instrument towards the detection of haemoglobinopathies, thalassemias and diabetes on one blood card sample. The software was tested for its efficiency and accuracy on 171 blood samples rendering 30-fold faster analysis with less bias and rounding errors in comparison with the manual approach. In this study, we identified the variability associated with the disease biomarkers in healthy individuals and successfully applied predictive models to detect blood abnormalities. Taken together, we demonstrated in this study that population screening of multiple blood disorders is made possible using MALDI-ToF technology in combination with automated software tools.